Floatz logo

Cholestyramine

Hepatocellular Cancer (HCC)

Daiichi SankyoOtherPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Hepatocellular Cancer (HCC) cohort.

Asset / SponsorPhaseRating
u3-1784
Daiichi Sankyo
Phase 1CC
Compound Mylabris
Shanghai Zhongshan Hospital
D
Carmofur
Shanghai Zhongshan Hospital
D

Same molecule, other indications

Cholestyramine is also rated in:

multiple sclerosisDormant
B
Indicative ·
59 / 100
View asset →
metabolic dysfunction-associated steatotic liver diseaseDormant
B
Indicative ·
57 / 100
View asset →
metabolic dysfunction-associated steatohepatitisDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →